IGC Pharma (IGC) vs Quince Therapeutics (QNCX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
IGC Pharma (IGC) has outperformed Quince Therapeutics (QNCX) over the past year, losing 32.2% versus a loss of 92.4%. Over five years, IGC leads with a -80.5% price change compared with -99.8% for QNCX. Quince Therapeutics is the larger company by market cap ($29.9 million vs $29.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IGC | QNCX |
|---|---|---|
| Share price | $0.2849 | $29.36 |
| Market cap | $29.45M | $29.86M |
| 1-day change | +1.75% | +9.88% |
| YTD return | +1.75% | -95.62% |
| 1-year return | -32.17% | -92.35% |
| 5-year return | -80.49% | -99.77% |
| EPS (TTM) | $-0.07 | $-214.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $0.45 | $910.00 |
| 52-week low | $0.24 | $15.10 |
| Distance from 52-week high | -36.69% | -96.77% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +2006.00% | +156.91% |
| Average volume | 704.91K | 28.83K |
| Shares outstanding | 103.38M | 1.02M |
| Employees | 70 | 38 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IGC has outperformed QNCX by 60.2 percentage points over the past year.
About IGC Pharma
IGC stock →IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's.
Healthcare · Biotechnology · 70 employees
About Quince Therapeutics
QNCX stock →Quince Therapeutics, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises eDSP, which is in Phase 3, for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.
Healthcare · Biotechnology · 38 employees
IGC vs QNCX FAQ
Which is bigger, IGC Pharma or Quince Therapeutics?
Quince Therapeutics (QNCX) is larger, with a market capitalization of $29.86M compared with $29.45M for IGC Pharma (IGC).
Which stock has performed better over the past year, IGC or QNCX?
IGC returned -32.17% over the past 12 months, compared with -92.35% for QNCX (price return, excluding dividends). Past performance does not predict future results.
Are IGC Pharma and Quince Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.